Status:
COMPLETED
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
Lead Sponsor:
Minia University
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision. It is also a leading cause of visual decline in younger patients, especially in developing countries like ou...
Detailed Description
The investigators randomly assigned four hundreds eyes of diabetic patients with central diabetic macular edema for intra-vitreal injection of AVEGF group I (200 patients eyes) received aflibercept 2....
Eligibility Criteria
Inclusion
- Patients with type 1 or 2 diabetes mellitus with central DME clinically as well as documented by optical coherence tomography (OCT) imaging
- The age of the patients at least 20 years old
- Patients not receiving AVEGF injection, at least for one year
- The BCDVA letter score of at least one eye (range, 0 to 115, with higher scores indicating better visual acuity of 90 (Snellen = 20/32) to 40 (Snellen = 20/320) and central DME .
Exclusion
- Patients with cataract
- Glaucoma patient
- Previous AVEGF injection in less than one year
- Patients not attending all of the scheduled follow up visits
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04087746
Start Date
January 1 2017
End Date
June 1 2019
Last Update
September 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minia University
Minya, Egypt